Songyun L. Ouyang

Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Correction: Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.

Correction: Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.

Journal: British journal of cancer
Published: September 02, 2026

LGMN promotes crosstalk between macrophages and fibroblasts in pulmonary fibrosis: a potential therapeutic target.

LGMN promotes crosstalk between macrophages and fibroblasts in pulmonary fibrosis: a potential therapeutic target.

Journal: Frontiers in immunology
Published: January 17, 2026

The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC.

The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC.

Journal: Cancer science
Published: November 27, 2025

An autoantibody signature targeting cuproptosis-related proteins for non-small cell lung cancer detection and prognosis.

An autoantibody signature targeting cuproptosis-related proteins for non-small cell lung cancer detection and prognosis.

Journal: PeerJ
Published: November 10, 2025

Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.

Anti-PDGFRα autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway.

Journal: British journal of cancer
Published: July 01, 2025

Gender-associated heterogeneity of F2RL3 methylation in peripheral blood highlights its associations with early-stage male lung cancer in the Chinese population.

Gender-associated heterogeneity of F2RL3 methylation in peripheral blood highlights its associations with early-stage male lung cancer in the Chinese population.

Journal: Cancer epidemiology
Published: March 20, 2025

Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea.

Circulating CHI3L1 autoantibodies serve as a diagnostic biomarker in patients with obstructive sleep apnea.

Journal: Scientific reports
Published: January 20, 2025

Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma.

Plasma anti-PRTN3 IgG and IgM autoantibodies: novel biomarkers for early detection of lung adenocarcinoma.

Journal: Frontiers in immunology
Published: November 25, 2024

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.

Journal: Journal for immunotherapy of cancer
Published: November 17, 2024

ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target.

ANGPTL4 mediated mesothelial-mesenchymal transition in pulmonary fibrosis: a potential therapeutic target.

Journal: Journal of translational medicine
Published: August 09, 2024

Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.

Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: July 28, 2024

Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels.

Predicting epidermal growth factor receptor (EGFR) mutation status in non-small cell lung cancer (NSCLC) patients through logistic regression: a model incorporating clinical characteristics, computed tomography (CT) imaging features, and tumor marker levels.

Journal: PeerJ
Published: July 16, 2024
Showing 1-12 of 35

Last Updated: 09/26/2026